BACKGROUND: Whether cannabis is a risk factor for cardiovascular events is unknown. We examined the association between smoking cannabis and cardiovascular events in a cohort of older veterans (66 to ...

BACKGROUND: Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of ...

BACKGROUND: Vascular aging is an important phenotype characterized by structural and geometric remodeling. Some individuals exhibit supernormal vascular aging, associated with improved cardiovascular ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

In the article by Martin et al, “2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association,” which published ahead of print on January 27, 2025, and ...

In the article by Martin et al, “2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association,” which published ahead of print on January 24, 2024, and ...

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity in hypertension. However, the impact of NAFLD and related fibrosis on hypertension and its control of cardiovascular disease (CVD) and ...

Joynt Maddox KE, Elkind MSV, Aparicio HJ, Commodore-Mensah Y, de Ferranti SD, Dowd WN, Hernandez AF, Khavjou O, Michos ED, Palaniappan L, et al; American Heart Association. Forecasting the burden of ...

Cardiac fibrosis is an important disease determinant of heart failure progression. Studies in animal models have shown preservation of cardiac function and delayed heart failure progression through ...

Preventive therapy for cardioembolic stroke in patients with atrial fibrillation is anticoagulation, and current guideline recommends direct oral anticoagulants (DOACs) as alternatives to vitamin K ...

Arrhythmogenic cardiomyopathy (ACM) is a heritable heart muscle disease associated with increased risk of sudden cardiac death. The only treatment proven to reduce this risk is an implantable ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors exert outstanding benefits on heart failure (HF) both with reduced ejection fraction (HFrEF) and with preserved ejection fraction. However, the ...